MediciNova : Corporate Presentation – March 15, 2024

MediciNova Corporate Presentation

Forward-Looking Statements

Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding MediciNova's clinical trials supporting the safety and efficacy of its product candidates and the potential novelty of such product candidates as treatments for disease, plans and objectives for clinical trials and product development, strategies, future performance, expectations, assumptions, financial condition, liquidity and capital resources. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166,MN-221,MN-001, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," "considering," "planning" or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166,MN-221,MN-001, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, risks related to MediciNova's reliance on the success of its MN-166 and MN-001 product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2023 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of March 15, 2024. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

2 © MediciNova, Inc.

MediciNova's mission is to develop promising new therapeutics for the treatment of diseases with high unmet medical needs.

3

MediciNova Overview

Late-stage biopharma company developing oral, anti-inflammatory candidates with well-established safety and efficacy profiles

• Differentiated product profiles have potential to meet needs of patients across a wide range of indications
• Targeting large, underserved, markets

Robust pipeline focused on neurological, fibrotic, and other diseases with no or inadequate treatment options

• MN-166(ibudilast): targeting CNS disorders with high unmet needs, including Phase 3 programs in ALS and DCM
• • Progressive MS program is Phase 3 ready
  • Other programs in ARDS, glioblastoma, CIPN, substance dependence, and Long COVID
• MN-001(tipelukast): Phase 2 for NAFLD

Well-funded with capital efficient business model

4 © MediciNova, Inc.

MN-166

Ibudilast

6

Amyotrophic Lateral Sclerosis (ALS) Landscape

MN-166 (ibudilast) Advantages:

• Potential to improve survival compared to standard of care
• No serious safety issues (other ALS drugs have Warnings on the labels)

1. Source: ALS Association; 2. Source: Cowen & Co. estimate; 3. Cochrane Database of Systematic Reviews; 4. Radicava prescribing information; 5. Relyvrio prescribing information;

6. Qalsody prescribing information.

9 © MediciNova, Inc.